“An updated version of Moderna’s Covid-19 vaccine that targets two coronavirus types (known as a “bivalent” vaccine) has today been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) for an adult booster dose. to meet the standards,” read an official government release on Monday.
Half of the booster, called “Spikewax Bivalent Original/Omicron,” targets the original coronavirus strain while the other half targets Omicron, it said.
The UK government said the decision to approve the shot was approved by the MHRA, the government’s independent expert scientific advisory body, after a careful review of the evidence.
The MHRA described the side effects as similar to the original Moderna booster dose and found them to be “generally mild and self-resolving”.
“No serious security concerns have been identified,” a UK government release said.
“The first generation of Covid-19 vaccines used in the UK are providing significant protection against the disease and saving lives. This bivalent vaccine is a sharp tool in our arsenal as it helps protect us against the disease as the virus continues to develop.”
It is not yet clear who or when the booster will be given. The UK’s Joint Committee on Immunization and Immunization (JCVI) will advise on the rollout of the vaccine.
“This marks the first authorization of a bivalent vaccine containing Omicron, a bivalent vaccine with an important role in protecting people in the UK from Covid-19 as we enter winter,” he said.